MiniMed Group (MMED)
Builds integrated insulin-delivery and glucose-monitoring systems for diabetes care.
$20.68
vs last close−0.52 (−2.48%)
In millions of USD, except per-share figures
| In millions | Q4 FY24Apr 2025 | Q2 FY25Oct 2025 | Q3 FY25Jan 2026 | Q4 FY25Apr 2026 | Q1 FY26Jul 2026 |
|---|---|---|---|---|---|
| Revenue | 724 | 752 | 790 | 837 | 843 |
| Cost of revenue | 321 | 324 | 428 | 357 | 378 |
| Gross profit | 402 | 428 | 362 | 480 | 465 |
| 607 | 438 | 455 | 398 | 427 | |
| Research & development | 109 | 111 | 114 | 99 | 115 |
| 327 | 318 | 309 | 299 | 312 | |
| Selling & marketing | 327 | 0 | 309 | 0 | 0 |
| Other expenses | 171 | 9 | 32 | 0 | 0 |
| Operating income | −204 | −10 | −93 | 82 | 38 |
| 0 | −2 | −6 | −172 | −34 | |
| Other non-operating income | −166 | 0 | 6 | 0 | 0 |
| Income before tax | −204 | −12 | −99 | −90 | 4 |
| Income tax expense | 17 | 19 | 12 | 93 | 4 |
| Net income from continuing operations | −221 | −31 | −111 | −183 | 0 |
| Other adjustments | 2 | 1 | 0 | 0 | 0 |
| Net income | −209 | −27 | −119 | −183 | 0 |
| EPS, basic | $0.00 | $0.00 | −$0.42 | −$0.68 | $0.00 |
| EPS, diluted | $0.00 | $0.00 | −$0.42 | −$0.68 | $0.00 |
| Weighted average shares, basic | 0 | 0 | 281 | 268 | 281 |
| Weighted average shares, diluted | 0 | 0 | 281 | 268 | 281 |
| EBITDA | 0 | 29 | −60 | 82 | 38 |
| Depreciation & amortization | 38 | 39 | 39 | 0 | 0 |
| EBIT | −38 | −10 | −99 | 82 | 38 |